Cocaine Screen With Reflex Confirmation, Whole Blood
Use
This test is intended for the detection of cocaine use by screening whole blood samples. The initial screening is performed using an immunoassay at a threshold of 25 ng/mL. Presumptive positive results are confirmed by a highly specific chromatography mass spectrometry, allowing for definitive identification and quantitation of cocaine or its metabolites to help clinicians assess potential drug use or exposure.
Special Instructions
The test employs a two-step process where initial screening is conducted via immunoassay and subsequent confirmation using chromatography mass spectrometry. It is important to handle specimens properly, ensuring they are stored and transported under the correct conditions to avoid degradation that may affect test results.
Limitations
The test has been developed by LabCorp but not cleared by the FDA, which implies it may not have undergone the exhaustive review typical of approved assays, possibly affecting interstate recognition and acceptance. The test's performance and outcomes are reliant on the integrity and handling of the blood sample, and improper sample storage or handling could lead to diminished result validity.
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 73823-7
- 48947-6
- 18208-9
- 43230-2
Result Turnaround Time
4-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
7 mL
Minimum Volume
3 mL
Container
Gray-top (sodium fluoride/potassium oxalate) tube, green-top (heparin) tube, or lavender-top (EDTA) tube
Storage Instructions
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.